Experimental Therapeutics Program

Program Leader

Anton Wellstein, MD, PhD

Program Overview

The overall mission of the Experimental Therapeutics (ET) Program is to reduce the cancer burden through preclinical and early clinical drug development, to determine optimal treatment approaches, combinations and sequences, and to identify prognostic, predictive and surrogate markers of efficacy and resistance for active agents.

ET has 40 full members and 34 associate members, including translational and clinical researchers, representing a variety of departments at Georgetown University and MedStar Health. The program is organized by disease and modality groups to focus clinical research activities and prioritize clinical trials.

The Cancer Center has recruited leaders in the field that have enhanced the program’s focus, breadth and depth, and has established the MedStar Georgetown Cancer Network to facilitate clinical research across MedStar institutions. The program’s commitment to increasing accrual to clinical trials is essential. Furthermore, the expansion of trials to other institutions in the MedStar Georgetown Cancer Network is enhancing the availability of cutting-edge clinical research to patients in the catchment area.

Experimental Therapeutics Program member research has three specific aims:

  • Aim 1: Targeting known driver pathways of cancer
  • Aim 2: Targeting the tumor microenvironment  and the immune system
  • Aim 3: Developing drugs and biomarkers for cancer diagnosis, prognosis and therapy

Full Members

Associate Members